Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- resistant cervical dystonia

Neurology

Volumn 53, Issue 7, 1999, Pages 1431-1438

  Brin, M F ^a   Lew, M F ^b   Adler, C H ^c   Comella, C L ^d   Factor, S A ^e   Jankovic, J ^f   O'Brien, C ^g   Murray, J J ^h   Wallace, J D ⁱ   Willmer Hulme, A ⁱ   Koller, M ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e ALBANY MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g Colorado Neurological Institute ^*  (United States)

^h PRA International USA   (Netherlands)

ⁱ Athena Neurosciences Inc   (United States)

Author keywords

BoNT B; Botulinum toxin type B; Cervical dystonia; Clinical trials; NeuroBloc; Torticollis

Indexed keywords

BOTULINUM TOXIN B; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ADULT; AGED; ARTICLE; CERVICAL SPINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; FEMALE; HUMAN; INFECTION; INTERNALIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHIZOTOMY; TORTICOLLIS; XEROSTOMIA;

EID: 0032716402     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1431     Document Type: Article

References (38)

1. Nutt JG, Muenter MD, Melton LJI, Aronson A, Kurland LT. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988;50:361-365.
2. Chan J, Brin M, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991;6:119-126.
3. Brin MF. Torticollis (cervical dystonia). In: Johnson RT, Griffin JW, eds. Current therapy in neurological diseases. 4th ed. St. Louis: Mosby Year Book, 1993:266-270.
4. Jankovic J, Leder S, Warner I, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41:1088-1091.
5. National Institutes of Health. Conference report, clinical use of botulinum toxin. National Institutes of Health consensus development conference statement. Arch Neurol 1991;48: 1294-1298.
6. Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. J Neurol Neurosurg Psychiatry 1992;55:229-231.
7. Gauthier S. Idiopathic spasmodic torticollis: pathophysiology and treatment. Can J Neurol Sci 1986;13:88-90.
8. Brin MF. Treatment of dystonia. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. New York: Williams & Wilkins, 1998:553-578.
9. Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases. Surg Neurol 1993;40:96-103.
10. Braun V, Richter HP. Selective peripheral denervation for the treatment of spasmodic torticollis. Neurosurgery 1994;35:58-56.
11. Tsui J, Eisen A, Stoessel AJ, et al. Double-blind study of botulinum toxin and spasmodic torticollis. Lancet 1986;2:245-246.
12. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
13. Boghen D, Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. Eur Neurol 1993;33:199-203.
14. Moore AP, Blumhardt LD. A double-blind trial of botulinum toxin"A"in torticollis with one year follow up. J Neurol Neurosurg Psychiatry 1991;54:813-816.
15. Green P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
16. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonia patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.
17. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: Das Gupta BR, ed. Botulinum and tetanus neurotoxin: neurotransmission and biomedical aspects. New York: Plenum Press, 1993:651-654.
18. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
19. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
20. Zuber M, Sebald M, Bathien N, Derecondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type-A botulinum toxin - frequency and significance. Neurology 1993;43: 1715-1718.
21. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: Das Gupta BR, ed. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York: Plenum Press, 1993:651-654.
22. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
23. Martin TFJ. Stages of regulated exocytosis. Trends Cell Biol 1997;7:271-276.
24. Schiavo G, Benefenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992;359:832-835.
25. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP 25. Nature 1993;365:160-163.
26. Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions, and antibodies. In: Moore P, ed. Handbook of botulinum toxin treatment. London: Blackwell Science, 1995:16-27.
27. Das Gupta BR, Sugiyama H. Molecular form of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immunol 1976;14:680-686.
28. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-194.
29. Siegel LS. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid. J Clin Microbiol 1989;27:1906-1908.
30. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
31. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies. Correlation with clinical response. Neurology 1998;50:1624-1629.
32. Consky ES, Basinski A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 1991;40(suppl 1):445. Abstract.
33. Consky ES, Lang AE. Assessment of cervical dystonia: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin, neurological disease and therapy series. Vol. 25. New York: Marcel Dekkar, 1994:224-226.
34. SAS Institute Inc. SAS/STAT user's guide, version 6. 4th ed., vol. 1. Cary, NC: SAS Institute, 1989:943.
35. SAS Institute Inc. SAS/STAT user's guide, version 6, 4th ed., vol. 2. Cary, NC: SAS Institute, 1989:846.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
37. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
38. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A - responsive cervical dystonia patients. Neurology 1999;53:1439-1446.